Drug solution for bone fracture nonunions - OSTEOforUNION Skip to main content

01.01.2025

Genera Research Ltd.

Drug solution for bone fracture nonunions - OSTEOforUNION

OSTEOforUNION is a clinical-stage bone regeneration project focused on the development of OSTEOGROW-C, a personalized biological implant for the treatment of fracture non-unions. The project addresses a major unmet medical need in patients whose fractures fail to heal adequately, where current treatment often relies on autologous bone grafting and additional invasive surgery. OSTEOGROW-C combines recombinant human bone morphogenetic protein 6 (rhBMP6), the patient’s own autologous blood coagulum (ABC), and TCP ceramics to create a personalized implant that stimulates local bone formation and provides structural support at the fracture site.


The OSTEOforUNION project aims to advance OSTEOGROW-C toward clinical validation, regulatory approval and commercialization. The technology is prepared directly in the operating room using only a small amount of the patient’s own blood, with the goal of avoiding the need to harvest autologous bone from the iliac crest and thereby reducing procedure-related burden and complications. The project builds on Genera Research’s proprietary OSTEOGROW platform and is intended to establish a new regenerative treatment approach for fracture non-unions, with potential future expansion into spinal, long-bone and dental indications.


The broader objective of OSTEOforUNION is to develop a scalable and clinically relevant regenerative medicine platform that uses the patient’s own biology to promote bone healing, while supporting the transition of OSTEOGROW-C from clinical development toward routine medical use and international commercialization.



Exhibitor Data Sheet
Return to top